CTRI/2018/04/013349已完成2 期
An open label pilot study to evaluate safety and efficacy of Unani formulations (coded) PTV-6, PTV-7 (oral) and TA-1 AND TA-1 plus (topical) in Vitiligo patients of different skin grades - PS/PP
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Known cases of Vitiligo with any duration of disease, site, extension and distribution of vitiligenous lesions.
- •2. Either sex, age range 13â??50 years, with or without family history.
- •3. Willingness to participate in the study and to give written informed consent.
排除标准
- •1. Subjects having any systemic disease and other skin diseases.
- •2. Subjects with known allergies.
- •3. Impaired Cardiac, Hepatic and Renal function
- •4. Use of any other medications of allopathic and alternative system origin for the disease.
- •5. Concomitant use of any other antioxidants
- •6. History of hypersensitivity to any of the investigational drugs/herbal medicine.
- •7. Any medical condition, where physician feels participation in the study could be detrimental to subjects well being.
- •8. Pregnant and lactating women.
研究者
相似试验
进行中（未招募）
1 期
A phase 2a trial to evaluate the safety and tolerability of LUM001 in subjects with Primary Sclerosing Cholangitis (PSC) during 14 weeks of treatment.Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology.PSC is characterized by inflammation and fibrosis of the intra- and extrahepatic biliary tree resulting in diffuse multifocal stricture formation leading to biliary cirrhosis, portal hypertension and liver failure. PSC is a life-threatening and debilitating disease. The median survival from diagnosis in symptomatic patients with PSC has been estimated to be 12 years.MedDRA version: 17.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2014-005558-21-GBumena Pharmaceuticals LLC20
招募中
不适用
Study of Enhancer Along With Vaccination Against SARS-CoV-2 Virus InfectioCTRI/2022/03/040990Dr Shalini Srivastava
已完成
不适用
Safety of turmeric-boswellia product in healthy peopleCTRI/2022/02/040107Arjuna Natural Private Limited
已完成
不适用
To study the safety of Ashwagandha extract in healthy peopleCTRI/2022/08/044636Arjuna Natural Private Limited62
已完成
不适用
A study to test the efficacy and safety of the Zip-stitch device in patients with minor lacerationsCTRI/2022/09/046040Simplified Healthcare Pvt Ltd